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Abstract
Background: The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results
for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of
this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers
that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows:
I Adherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of
DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype).
II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when
informed that their oral dose of NRT was tailored to genotype rather than phenotype.
Methods/Design: An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or
more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly
allocated to one of two groups:
i. NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype), or
ii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)
The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit
attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not
abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically
validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing
sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the
5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting
will be compared between arms using an independent samples t-test and by estimating the 95% confidence
interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make
another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II).
Discussion: This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication
using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of
interventions of this kind are discussed.
Trial details: Funder: Medical Research Council (MRC)
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Background
Adherence to nicotine replacement in smoking cessation
is widely perceived to be problematic; educating smo-
kers about nicotine replacement use with generic or tai-
lored feedback does not readily alter behaviour [1,2].
There are, however, high expectations of the potential
for DNA-based risk information to motivate behaviour
change more strongly than other types of risk informa-
tion [3-5]. Such expectations are consistent with the-
ories of attitude change which predict that the greater
the personal salience of information, such as informa-
tion regarding one’s own DNA, the greater its impact
[6]. We present here a protocol for a randomised con-
trolled trial assessing the impact on adherence of pre-
scribing a tailored oral dose of nicotine replacement
therapy (NRT) based on genotype assessing smokers’
receptivity to nicotine, compared with a prescription tai-
lored on nicotine dependence (phenotype). The beha-
vioural effect will be measured by the proportion of all
prescribed NRT consumed.
It is well-established that both the initiation and main-
tenance of smoking have high heritability [7-9]. There is
also growing evidence that some of the variability in
responsiveness to smoking cessation pharmacotherapy,
such as NRT or bupropion, is explained by genotype
[10-12]. The Asn40Asp (A118G) polymorphism
(rs1799971), found in exon I of the OPRM1 gene, has
been associated with functional changes in mu-opioid
receptors [13]. This mis-sense SNP leads to the substitu-
tion of an asparagine (Asn) for an aspartate (Asp) at
position 40 in the amino acid sequence. The Asp (G)
allele has been shown to bind beta-endorphin three
times more strongly than the Asn (A) allele [14],
although two replication studies failed to find this
[15,16]. The Asp (G) allele has also been associated with
reduced expression of the receptor [16]. Thus, for exam-
ple, smokers with a particular variant in the mu-opioid
receptor (OPRM1) gene (Asp40, present in about 25% of
the population) that regulates the binding affinity of
beta-endorphins, have been reported to show double the
s h o r tt e r mq u i t - r a t e sw h e nu s i n gaf o r mo fN R Tw i t h
higher levels of replacement compared with NRT that
results in lower levels of replacement [17]. Those homo-
zygous for the more common variant (Asn40) were
equally likely to stop smoking regardless of the level of
NRT replacement. These results support the hypothesis
that smokers with one or more copies of the Asp40 var-
iant are more likely to stop smoking following higher
doses of NRT than are smokers without this variant.
Although this association was not replicated in a more
recent study [18], the earlier research provides face
validity for an exploration of the motivating impact of
such DNA based information on smoking cessation.
Genetic tests are now available via the Internet (e.g.
Respiragene http://www.synergenz.com), which, it is
claimed, may be used to identify the optimal pharma-
cotherapy for an individual wishing to stop smoking or
motivate an individual to stop smoking. The impact of
such testing on smoking cessation behaviour is currently
unevaluated but it has the potential to increase quit
rates in two key ways. Firstly, by more effective prescrib-
ing i.e. prescribing that is tailored to the individual’s
nicotine metabolism to avoid over-prescribing with con-
sequent lack of adherence or under-prescribing with
consequent urges to smoke; and secondly, by increasing
expectations of treatment effectiveness, and hence moti-
vation to comply with the treatment. The focus of the
current trial is upon the latter. There is growing evi-
dence to suggest that perceiving a health problem to
have a genetic cause increases the perceived effective-
ness of taking medication to deal with the problem [19].
This has been documented for depression, heart disease
and stopping smoking [20-23]. Given perceived treat-
ment effectiveness predicts treatment use, tailoring
treatment on the basis of genetic testing has the poten-
tial to improve treatment outcomes by increasing adher-
ence. These observations inform the scientific rationale
and principal hypothesis for the current trial.
A preliminary study suggests that prescribing based on
genetic testing has the potential both to facilitate cessa-
tion by increasing the attractiveness of effective pharma-
cological treatments, as well as to undermine it, by
decreasing the perceived importance of willpower in
smoking cessation [23]. In this experimental analogue
study, smokers who were asked to imagine that they
had a gene variant that predicted a good response to
bupropion, a medicine used to facilitate smoking cessa-
tion, were more likely to select the use of bupropion,
the more effective treatment given their gene variant, to
assist them in quitting. They were, however, less likely
to perceive “willpower” as being important [23]. Other
studies also report that medication is perceived as more
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[20-22]. In one such study, smokers who were rando-
mised to receive feedback of genetic susceptibility to
lung cancer perceived NRT as more helpful when quit-
ting, compared to the group not receiving genetic feed-
back [24].
W ep r e d i c tt h a tp r e s c r i b i n gt a i l o r e dt og e n o t y p e
increases adherence to NRT compared with prescribing
tailored to phenotype, by strengthening the perceived
effectiveness of the medication, a good predictor of
adherence [25]. Consumption of NRT directly increases
the likelihood of sustained smoking cessation; this being
dose-dependent in that the more NRT consumed, the
greater the chance of sustained cessation [26,27]. It is the
most popular medication used in UK NHS clinics [28].
Furthermore, given the common representation of genes
as deterministic, conferring immutable effects, it is impor-
tant to document the impact of DNA testing for nicotine
responsiveness in the longer term upon attributions for
failure to quit smoking among those smokers who do not
quit. Informing patients that their prescription is tailored
to their genotype may have negative effects through
engendering a sense of fatalism, which is associated with
perceiving a genetic cause to a health problem [29]. Such
fatalistic responses are predicted to result in reduced moti-
vation in this group to make a future quit attempt
(amongst those who fail to quit by six months).
Objective and hypotheses
We will estimate the impact upon adherence to NRT of
informing smokers that their oral dose of NRT has been
tailored on the basis of DNA analysis.
The trial tests two hypotheses:
I Adherence to NRT is greater among smokers who
are informed their oral dose of NRT is tailored to an
analysis of DNA (genotype), compared to one tai-
lored to nicotine dependence (phenotype).
I IA m o n g s ts m o k e r sw h of a i lt oq u i ta ts i xm o n t h s ,
motivation to make another quit attempt is lower
when informed that their oral dose of NRT was tai-
lored to genotype rather than phenotype.
While the trial is not powered to assess long term
behavioural outcomes related to smoking, prolonged
abstinence is measured at six months post quit date.
Methods/Design
Trial Design (see Figure 1)
An open label, parallel group, randomised controlled
trial in which participants were randomly allocated on a
1:1 basis to one of two groups:
i. NRT oral dose tailored by DNA analysis, or
ii. NRT oral dose tailored by nicotine dependence
score
Study Setting
The trial is taking place in National Health Service
(NHS) smoking cessation clinics in primary care. These
provide a combination of weekly behavioural support
and pharmacotherapy to assist smokers to quit. Partici-
pants are being recruited from 29 primary care practices
in two English cities, Birmingham and Bristol.
Participants
The sample will comprise 630 smokers using NHS stop
smoking services within primary care. To be included,
participants must be aged 18 years or older and a regu-
lar cigarette smoker who wants to stop smoking. A ‘reg-
ular smoker’ is defined here as someone who has
smoked an average of 10 or more cigarettes per day
(including roll-ups) over the preceding 12 months. They
must also be able to give informed consent to partici-
pate as well as to be able to complete the study ques-
tionnaires, either alone or with assistance.
Exclusion criteria:
1. Cigar, pipe and oral tobacco users who do not
also smoke 10 or more cigarettes per day.
2. Those who meet the criteria contra-indicating NRT
use, as described in the Summary Product Characteris-
tics, updated by recent MHRA guidance. Although not
all forms of NRT are contra-indicated in pregnancy or
lactation, the metabolism of nicotine changes and
there remain concerns about safety in this group
which include the avoidance of 24 hour patches as
described in our protocol. Therefore pregnant or lac-
tating women or those who plan to become pregnant
during the course of treatment will be excluded.
3. Those with previous severe adverse reactions to
NRT patch or to oral NRT.
4. Those currently taking either medication for
smoking cessation that they are unwilling to stop
taking medication with a known influence on smok-
ing cessation that they should not stop (e.g. nortrip-
tyline for depression).
5. Those who are non-English speakers.
6. Those deemed unsuitable for the study by their
primary care physicians.
Genetic testing
All participants will give a sample of either blood or sal-
iva for genotyping, although the results are only used
for tailoring dose of oral NRT and communicated to
participants in the intervention group.
Marteau et al. BMC Public Health 2010, 10:680
http://www.biomedcentral.com/1471-2458/10/680
Page 3 of 10This trial tests for variants in the mu-opioid receptor
gene, OPRM1.I ti se x p e c t e dt h a ta b o u t7 5 %w i l lb e
homozygous for Asn40, with about 25% heterozygous or
homozygous for Asp40 (i.e. need the higher dose of
NRT) [18]. DNA will be extracted from blood using com-
mercially available methods. From participants who do
n o tw a n tt oh a v eab l o o dt e s t, DNA will be extracted
from saliva. Briefly, DNA is extracted using a standard
“salting out” technique [30]. For the genotyping of the
OPRM1 A118G polymorphism, PCR is carried out using
an allele specific, two-tube primer method. The reaction
mixture contained 0.5 μM of each OPRM1 and control
primer, approximately 150 ng of DNA, 200 μM dNTPs, 2
mM MgCl2 and 0.5 units of Taq polymerase in a final
volume of 25 μl. After an initial denaturation step for 10
min at 95°C, thermocycling consisting of 30 cycles of 95°
C for 20 sec, 68°C for 45 sec, 72°C for 30 sec. A final
extension phase of 72°C is followed by cooling of samples
to 4°C. PCR products are separated on a 1% agarose gel
at 200 V for 30 min and visualised using ethidium bro-
mide. In order for samples to be valid, a 750 bp control
product has to be formed in both allele specific reactions.
A homozygote is indicated by the presence of a 561 bp
product in one of the reactions and a heterozygote is
represented by a 561 bp product in both of the reactions.
A greater than 95% success rate is expected for the
extraction and amplification of DNA. In the event that
DNA is not collected or laboratory procedures fail to
extract and amplify the DNA from the sample, the parti-
cipant will be asked to provide a further sample.
Trial medication
The trial will take place in the context of NHS stop
smoking services, which provide behavioural support
and medication to assist smoking cessation. At the time
that this trial started, more than 70% of smokers in
these clinics used nicotine replacement therapy (NRT)
[28]. Current best practice is to use NRT in combina-
tion with behavioural support [31,32]. Smokers in the
current trial will all be prescribed NRT patches plus
oral NRT ‘top-up’ medication, which is approximately
35% more effective than NRT patch alone [33]. NRT
patch dose will be tailored in the same way in both
arms of the trial, namely according to how many cigar-
ettes are smoked per day. Oral NRT dose will be deter-
mined on a different basis in each arm of the trial: those
i nt h eg e n o t y p ea r mw i l lh a v et h ed o s et a i l o r e da c c o r d -
ing to the OPRM1 variant that they carry; those in the
phenotype arm will have the dose tailored according to
their nicotine dependence. Details of the basis for these
prescriptions are presented below. The aim of treatment
is to continue with full dose NRT for the first four
weeks after the quit day, after which medication is
reduced, according to patient need.
Figure 1 Trial flow diagram.
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All participants are to be offered behavioural support
and nicotine replacement therapy. The intervention to
which participants are randomised comprises the com-
munication that their dose for oral NRT treatment is
based on either genotype or phenotype.
Support for behavioural change
This is based on withdrawal orientated therapy [34] and
is provided for all participants twice prior to quit day
and weekly thereafter until four weeks after quitting and
then once more eight weeks after quitting. All nurses
have been trained to give behavioural support to NHS
standards [35]. The support lasts 10-30 minutes,
depending upon progress and stage of the quit attempt.
NRT patch prescription
All participants smoking 15 or more cigarettes per day
are prescribed 21 mg patches; those smoking 10-14
cigarettes per day will be prescribed 14 mg patches.
Oral NRT prescription
All participants will be offered additional oral nicotine
replacement (gum, microtabs, lozenges, or inhalator)
w i t ht h ec h o i c eo fd e l i v e r ys y s t e ml e f tt op e r s o n a lp r e -
ference. The dose of oral NRT prescribed is based on
delivered dose. Thus, a 2 mg gum delivers about 1 mg
of NRT into the circulation, and a 10 mg inhalator car-
tridge delivers about 3 mg of NRT.
i. Genotype arm (Intervention) Participants will be
informed that their oral dose of NRT is based on their
genetic test result, using the following script:
“Your extra NRT is based on the results of a genetic
test. We did a genetic test on the blood sample that
you gave last week. People have different versions of the
‘OPRM1’ gene. This gene influences how dependent you
are on nicotine. There is more information on genes in
the leaflet. Based on the results of your genetic test, you
a r em o r el i k e l yt ob es u c c e s s f u li ns t o p p i n gs m o k i n gi f
you have a (standard dose/higher dose)o fe x t r aN R T .
Recent research shows that people with your genetic
test result are more successful at stopping smoking if
they take all of the extra NRT, as well as using their
patch.
Y o us h o u l dw e a ran e wp a t c hf o r2 4h o u r se a c hd a y
for at least four weeks. The patch works by releasing a
steady dose of nicotine into your blood stream. You have
also been given a (dose/high dose) of extra NRT. Please
u s et h i sa sw e l la sw e a r i n gt h ep a t c h .Y o um a yw i s ht o
take it when you get a craving, but you can also take it
at other times of the day. Even if you feel you don’t need
the extra NRT, you should take it. Many quit attempts
fail because people don’t take enough NRT or stop taking
it before they have beaten their withdrawal symptoms.
Remember that this dose has been calculated to suit
your individual needs - try to stick to this amount each
day in addition to wearing the patch.”
Participants with the Asn variant will be advised to
take additional NRT equivalent to the delivery of 6 mg
of NRT a day. Those with the Asp variant will be
advised to take additional NRT equivalent to delivery of
12 mg a day. A rationale booklet will be given to each
participant describing:
i. their personalised additional oral dose of NRT
based on their genetic test result. Participants with
the Asn variant will be informed that they need a
standard dose of additional NRT and participants
with the Asp variant will be informed that they need
a higher dose of additional NRT;
ii. the basis upon which this dose was calculated (ie
a genetic test to establish which version of the
“OPRM1“ gene they carry);
iii. information about genes;
iv. information about the amount of additional NRT
they should take in addition to wearing a new patch
every day for at least 4 weeks;
v. the physiological mechanisms by which wearing
their NRT patch and taking all their personalised
dose of additional NRT each day for four weeks
increases their chances of stopping smoking.
ii. Phenotype arm (Comparison) Participants will be
informed that their oral dose of NRT is based on their
nicotine dependence scores from questionnaire answers,
using the following script:
“Your extra NRT is based on the results of the ques-
tionnaire you completed last week. The questionnaire
shows how dependent you are on nicotine. Based on
the results of this questionnaire, you are more likely
to be successful in stopping smoking if you have a
(standard dose/higher dose) of extra NRT. Recent
research shows that people who got this score on the
questionnaire are more successful at stopping smoking
if they take all of the extra NRT, as well as using
their patch.
Y o us h o u l dw e a ran e wp a t c hf o r2 4h o u r se a c hd a y
for at least four weeks. The patch works by releasing a
steady dose of nicotine into your blood stream. You have
also been given a (dose/high dose)o fe x t r aN R T .P l e a s e
u s et h i sa sw e l la sw e a r i n gt h ep a t c h .Y o um a yw i s ht o
take it when you get a craving, but you can also take it
at other times of the day. Even if you feel you don’t need
the extra NRT, you should take it. Many quit attempts
fail because people don’t take enough NRT or stop taking
it before they have beaten their withdrawal symptoms.
Remember that this dose has been calculated to suit
your individual needs - try to stick to this amount each
day in addition to wearing the patch.”
Participants scoring less than 7 on the Fagerström Test
for Nicotine Dependence (FTND - [36]) are categorised as
low dependence and those scoring 8 or above as high
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sample will score 7 or higher on the FTND [37]. Drawing
on usual practice in which dose is proportional to smoking
burden [38], those in the low dependence group will be
advised to take an additional amount of top up to deliver
6 mg of NRT. Those in the high dependence group will be
advised to take an additional amount equivalent to 12 mg
of NRT delivered a day.
Planned interim analysis (overseen by the Trial Steer-
ing Committee) including the first 160 participants
revealed a substantial difference between the number of
participants that obtained the higher dose of additional
NRT in the phenotype arm (n = 32) compared to the
genotype arm (n = 14). In order to balance the higher
and lower dose oral NRT in the two arms, a cut-off of 8
rather than 7 on the FTND will be used for the remain-
der of recruitment.
A rationale booklet will be given to each participant,
describing:
i. their personalised additional oral dose of NRT
based on their questionnaire responses. Participants
who score less than 8 (or 7, prior to an interim ana-
lysis) on the FTND are informed that they need a
standard dose of additional NRT; participants who
score above the cut-off are informed that they need
a higher dose of additional NRT;
ii. the basis upon which this dose was calculated (i.e.
responses to a questionnaire, revealing how depen-
dent they are on nicotine);
iii. information about the amount of personalised
additional NRT they should take in addition to
wearing a new patch every day for at least 4 weeks;
iv. the physiological mechanisms by which wearing
their NRT patch and taking all their personalised
dose of additional NRT each day for four weeks
increases their chances of stopping smoking.
Procedure
Participant recruitment
Smokers listed on the databases of participating general
practices will be written to inviting those wanting to
stop smoking to come into the trial. Those interested
will be invited to contact a research nurse to arrange to
attend a clinic at their general practice run by the
research nurse.
Consent process
Those wishing to participate will be asked to sign the
study consent form. Blood will be taken for DNA testing
from both groups and the baseline questionnaire will be
completed. A time will be arranged for the nurse to tel-
ephone to confirm participation and attendance at the
next clinic visit. Those confirming participation will
then be randomized.
Data collection
Participants will be asked to attend seven weekly clinic
sessions. In the first clinic participants will complete a
baseline questionnaire. NRT will be prescribed accord-
ing to the protocol at the second clinic visit and a quit
date agreed. All participants will be given a small card
summarising their top up dose of NRT and describing
the rationale for this, which will vary according to
whether it is tailored by DNA analysis or nicotine
dependence. In the third clinic a second questionnaire
will be completed. Participants are requested to con-
tinue to take their NRT as prescribed for four weeks
post quit attempt and to attend weekly clinic visits. All
participants will be contacted six months after their quit
dates to assess the study endpoints by questionnaires
sent by post or administered by telephone.
Outcomes
Hypothesis I
i) Primary outcome The primary outcome is adherence
to a 28-day prescription expressed as the proportion of
all NRT prescribed (in milligrams) that is consumed
each day in the first four weeks of quitting, averaged
over the four week quit period.
The proportion consumed will be measured by self-
report daily diary, backed up by pill counts. If pill counts
are discrepant with the diary, this will be discussed and
reconciled by the research nurse at the weekly clinic visit.
The adherence proportion on any day is the ratio of the
amount of NRT consumed to the amount prescribed.
The denominator of the amount prescribed derives from
both NRT patch and top up. For example, for someone
prescribed 1 × 21 mg patch and 6 × 1 mg oral NRT
doses (equivalent to 6 × 2 mg gums, for example), the
denominator is 27 mg. Consumption of the prescribed
top ups and any additional top ups taken will count
towards the total NRT consumed on a day. Wearing the
patch for 24 hours a day will count as the maximum
amount of NRT mg prescribed as having been consumed
from the patch. If the patch is worn for a fraction of the
24 hours (such as 12 hours) then this fraction of the total
NRT mg from the patch will be counted as having been
consumed (such as 0.5 × 21 mg for a 21 mg patch worn
for 12 hours), pro-rata. If the patch is not worn for 24
hours a day but additional oral NRT is taken then this
will count towards the total NRT consumed on that day.
For example, if someone prescribed a 21 mg patch and 6
mg of oral NRT, wears their patch for 16 hours a day and
uses an additional 7 pieces of gum to make up for the 7
mg of NRT lost by the patch coming off early, this will be
treated as 100% adherence (i.e. they have consumed 14 +
6 +7 = 27 mg). NRT consumed above that prescribed on
any day could occur through excess top up consumption
and will be treated as a daily proportion of 100%. The
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consumed, if, for example, a person has resumed
smoking.
Data quality for the primary outcome will be cate-
gorised into two main categories as ‘high’ or ‘lower’ for
analysis. High quality data consists of i) adherence data
that are validated by both the self-report daily diary and
the pill count at the clinic visit, or ii) data reporting the
resumption of smoking, whereby the participant informs
the research team that they abandoned their quit
attempt and resumed smoking. ‘Lower’ quality data con-
sists of all other permutations.
It is expected that the behavioural effects of the inter-
vention may be stronger in the first week of the quit
attempt as fewer participants will have resumed smok-
ing. Therefore a further short-term outcome is adher-
ence to NRT during the first 7 days of the quit attempt.
ii) Secondary outcomes
Adherence to all NRT prescribed, consumed in the
first seven days This will be assessed in the same way
as described for the primary outcome described above,
but using the time period of the first seven days of the
quit attempt.
Validated abstinence from smoking at 28 days and
six months At six months, 7-day point prevalence and
six month prolonged abstinence will be recorded. Point
prevalent abstinence is defined as smoking not more
than 5 cigarettes for the seven days prior to the assess-
ment confirmed by salivary cotinine < 15 ng/ml. Pro-
longed abstinence (defined as sustained abstinence after
an initial two week grace period as recommended by
Hughes and colleagues [39] will be operationalised by:
a) self-reported consumption of not more than five
cigarettes since the quit date; and b) salivary cotinine
levels of less that 15 ng/ml [40]. A 28-day abstinence
measure will also be reported, with validation by carbon
monoxide less than 10 ppm, with backward inference of
missing data from the 6 month measure following Rus-
sell standard criteria [40].
Hypothesis II
i) Within-subgroup outcome: Motivation to make
another quit attempt The sub-group comprises those
participants who fail to achieve prolonged abstinence at
the six month follow-up. The primary outcome within
this subgroup is motivation to stop smoking in the next
four weeks.
This is measured using the mean score of the following
four items measured using 7-point bipolar scales: “Do you
intend to stop smoking in the next 4 weeks?"[response
scale labelled at each end: “definitely do not” (1) and “defi-
nitely do” (7)]: “How likely is it that you will stop smoking
in the next 4 weeks?” ["very unlikely” (1), and “very likely”
(7)]; “How determined are you to stop smoking in the
next 4 weeks?” ["not at all” (1), and “extremely” (7)]; and
“How much do you want to stop smoking in the next 4
weeks?” ["not at all” (1), to “very much” (7)].
Sample size calculation
With 315 participants per arm, there is 90% power to detect
a 7.5% difference in the mean proportion of NRT con-
sumed using a two-tailed test at the 5% level of significance.
This is equivalent to detecting approximately a two days’
worth difference in mean NRT consumption over a 28-day
period. The calculation is based on the skewed distribution
of days of prescribed NRT patch use reported by Alterman
and colleagues [41] where 55% of participants reported high
use and the remainder had a uniformly spread distribution
of use. Assuming the same mixed distribution, with 50%
and 65% of high-use participants and the remainder uni-
formly distributed in the two arms, the implied difference
in mean consumption was 7.5%. By repeated random sam-
pling, the distribution of the mean within each group was
close to normal. The estimated pooled within-group stan-
dard error was 1.85%, and both Mann-Whitney and
unpaired t-tests provided at least 90% power.
Randomisation
Procedure
After receiving signed informed consent from a partici-
pant at the first clinic appointment (two week pre-quit),
the study nurse will telephone the participant to ensure
participation and commitment to the quit attempt. If
confirmed, the trial co-ordination team (KCL) will send
the participant’s data that are required for randomisa-
tion to the statistical team (Cambridge), and receive
back the identity of the allocated group.
Method
Each participant will be randomised to one of the two
arms on a 1:1 basis. The randomisation will be stratified
by nurse, cigarettes smoked per day (i.e., 10-14 or 15+)
and the Fagerström Test for Nicotine Dependence score
(< 7 (< 8) or 7-10 (8-10)). Within each stratum, a rando-
misation sequence will be generated using blocking, with
successive randomly selected blocks sizes of six, eight
and ten, in order to minimise predictability of assign-
ment. Families will be allocated as clusters to the same
arm to avoid contamination and reflect practice. First
participants from families will be assigned a group
according to the next blocked allocation in their stratum.
Concealment
At the start of the trial the randomisation sequence
in each stratum will be generated using randomly per-
muted blocks by the trial statistician and concealed
from the trial coordination team, therapists and partici-
pants. The statistical team will be given a participant’s
study identification code and the stratifier data necessary
for the participant’s randomisation. The only other
information sent will be the participant’sd a t eo fb i r t h
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between the sequence generated and that used in the
trial to be confirmed to have been securely operated.
After assignment, participants’ study arm will not be
concealed from participant, nurse or researchers. This
will include the nurses collecting the primary endpoint
data as they are also delivering the intervention. How-
ever, group allocation will be concealed from the
research team collecting secondary outcome data on
self-reported smoking status.
Fidelity checks
All sessions in which the rationale for the prescription
will be presented (ie the second session, one-week pre-
quit) will be tape-recorded. During the recruitment
phase of the trial, assessments of a subsample of ran-
domly selected recordings will be conducted to assess
the fidelity of intervention delivery. Subsequently, feed-
back will be provided to the nurses to optimise inter-
vention delivery. In addition, a sub-sample of these
recordings will be randomly selected and transcribed to
assess fidelity to the clinical protocol. The tapes will be
stored in a locked cabinet until the end of the trial and
completion of this analysis. They will be accessible only
to the study team.
Adverse events monitoring
At each of the weekly clinic visits following the quit
attempt, participants will complete a schedule of nico-
tine overdose symptoms. This assessment is recorded in
the Case Report Form, together with details of any
action taken (e.g. continuing with prescribed dose/
directing the participant to a lower dose). In addition, at
each weekly clinic visit, participants will be asked about
the occurrence of any significant side effects from their
treatment. The trial nurses will enquire about any
adverse events to determine their severity and provide
appropriate advice about their management (e.g. rotat-
ing the NRT patch site or use of emollients for skin
reactions). Examples of adverse events include symp-
toms of nicotine overdose (e.g. vomiting, headaches) and
adverse reactions to NRT (e.g. skin and subcutaneous
tissue disorders). All of these events as well as all com-
ments made by participants and health care profes-
sionals will be logged in the Trial Log File. Each event
will be given an individual number and logged in a com-
puter database. Any follow-up or further action needed
will also be logged. No personal information will be
included unless absolutely necessary. The Trial Log File
will be stored in a locked office.
Any incident judged to be serious by the principal
investigator and the research team will be reported to
the trials independent Data Monitoring Committee
within 24 hours. Any serious adverse events will be
reported to Medicines and Healthcare Products Regula-
tory Authority (MHRA).
Research Governance
This study is classified as a Clinical Trial of an Investi-
gational Medicinal Product (CTIMP) as it investigates
the efficacy of a medicine for which the prescribed dose
is determined by the results of genetic testing. Although
the trial participants may be prescribed NRT without
participating in the trial, the dosage and timing of the
prescription is determined by a clinical protocol and
therefore the Medicines for Human Use (Clinical Trials)
Regulations (2004), apply. Further information is avail-
able from the MHRA algorithm at http://www.ct-toolkit.
ac.uk. MHRA approval has been granted (MHRA ref:
24570/0002/001-0001; Eudract no: 2006-000106-24).
Ethical approval for the trial has been granted (Hert-
fordshire 1 Research Ethics Committee, ref: 06/Q0201/
21, approved 26
th June, 2006). R&D approval has been
granted from the relevant PCTs in Birmingham and
Bristol where the interventions will take place.
Statistical Analysis
All analyses will be primarily on an intention-to treat-
basis, with the intention to treat population defined as
those randomised into the trial. This compares the prag-
matic policies represented by the two intervention arms
amongst all those eligible and consenting. This will be
supported by an explanatory per protocol analysis, with
the per protocol population defined as all participants
with the exclusion of those who chose not to attend to
receive their allocated intervention.
Hypothesis I: Analysis of primary outcome
For the analysis of the primary outcome, the proportion
of all NRT consumed in the first 28 days of quitting will
be compared between arms using an independent sam-
ples t-test and by estimating the 95% confidence interval
for the observed between-arm difference in mean of
proportion of NRT consumed (Hypothesis I). This will
be confirmed using the nonparametric Bootstrap BCA
method for estimating the difference between two
means with confidence interval.
Secondary analyses
The proportion of all NRT consumed in the first seven
days of quitting will be compared as described for the
primary outcome. Measures of abstinence will be ana-
lysed between arms as the difference in proportions
with 95% confidence interval and chi-squared test.
Hypothesis II: within-subgroup outcome
Amongst those classified as not abstinent at the six
month follow-up, as judged by 7-day point prevalence
abstinence, an independent-samples t-test will be used
to compare motivation to make another quit attempt
between arms.
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The intervention effect will be estimated with 95% con-
fidence intervals for each trial nurse separately. A formal
test of whether the intervention effect varies significantly
by nurse will be assessed either by using an interaction
of nurse by intervention in a linear regression model, or,
if the assumptions are not met, by using a chi-squared
test of heterogeneity in a standard meta-analysis of the
nurse intervention effects, using estimates and standard
errors obtained using the bootstrap method for each
nurse. For ease of interpretation, the simpler interaction
test will be presented if results are not materially differ-
ent. The three other subgroup variables are study centre,
total daily NRT prescribed (20 mg, 27 mg, 26 mg, and
33 mg) and daily top up amount prescribed (Enhanced
oral NRT, Standard oral NRT). Subgroup analyses will
be confined to analysis of the primary outcome and will
use the same interaction analysis framework.
Handling missing data in the primary outcome
Analysis of adherence over the 28-day period will be pri-
marily on an intention to treat basis, involving all rando-
mised participants. If clinic non-attenders report
returning to smoking or cannot be contacted by the
nurse to establish adherence, then adherence will be
counted as zero for the remaining 28 day period. Missing
daily adherence data from those participants who
attended the clinic session will be imputed from the aver-
age taken from the days that are not missing. This analy-
sis will be supported first by an explanatory per protocol
analysis which excludes those participants not receiving
the intervention, and second, by a sensitivity analysis.
Design considerations
This is the first clinical trial evaluating the behavioural
impact on adherence of prescribing medication using
genetic rather than phenotypic information. There are
some specific issues in choice of design for trials of
interventions of this kind.
Our research questions ideally required us to rando-
mise the information concerning the basis for prescrib-
ing (i.e. telling the two groups that their prescriptions
depended on gene or nicotine dependence) and to hold
the NRT treatment constant across both groups. This
design was the most attractive experimentally, but unac-
ceptable on the grounds that it would have required us
to deceive participants about the true basis for their pre-
scriptions. We considered seeking informed consent to
this approach, but rejected it because of concerns that
this might undermine trust in the trial as a whole.
We therefore required a design which would result in
a balance of gene variants and nicotine dependence
across groups and would generate similar prescription
of NRT in both groups, despite the basis of prescription
(genotype or phenotype) varying systematically by
group. If by chance or systematic effect a greater dose
of NRT was prescribed in one group than the other,
then any apparent intervention effect on abstinence
might be due to more effective prescribing rather than
to differing expectations of effect of adherence.
We selected the design of an open-label, parallel
group randomised trial in which participants were ran-
domly allocated to one of two groups: oral NRT pre-
scribing tailored by DNA analysis, or oral NRT
prescribing tailored by nicotine dependence. We have
monitored prescriptions across the groups for the need
for a pre-determined change in threshold for definition
of heavy smoking in the phenotype group to assure
prescribing balance with the genotype group. We
defined adherence to NRT rather than abstinence from
smoking as our primary outcome, and adherence was
defined in terms of the proportion of NRT prescribed
that was consumed. This outcome is still open to the
impact of differential prescribing across groups as par-
ticipants might systematically consume less of a larger
dose. We will analyse genotype and recorded pheno-
type in both trial groups thereby allowing analysis to
indicate the extent to which any differences between
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